Summit Therapeutics Inc.
General ticker "SMMT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $15.9B (TTM average)
Summit Therapeutics Inc. does not follow the US Stock Market performance with the rate: -20.9%.
Estimated limits based on current volatility of 5.1%: low 21.91$, high 24.26$
Factors to consider:
- Total employees count: 159 as of 2024
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Third-party risks, Regulatory and compliance, Intellectual property risks
- Current price 13.9% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.39$, 22.08$]
- 2026-12-31 to 2027-12-31 estimated range: [5.89$, 16.38$]
Financial Metrics affecting the SMMT estimates:
- Negative: with PPE of -12.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.43 <= 0.07
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 87.71 > 64.25
- Positive: -4.45 < Investing cash flow per share per price, % of -1.31
Short-term SMMT quotes
Long-term SMMT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $89.74MM | $211.30MM | $1,094.42MM |
| Operating Income | $-89.74MM | $-211.30MM | $-1,094.42MM |
| Non-Operating Income | $-526.14MM | $-10.01MM | $14.84MM |
| Interest Expense | $16.46MM | $8.69MM | $0.00MM |
| R&D Expense | $59.47MM | $150.78MM | $537.67MM |
| Income(Loss) | $-615.87MM | $-221.31MM | $-1,079.59MM |
| Taxes | $-0.95MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-614.93MM | $-221.31MM | $-1,079.59MM |
| Stockholders Equity | $77.69MM | $388.75MM | $658.86MM |
| Assets | $202.95MM | $435.56MM | $751.18MM |
| Operating Cash Flow | $-76.76MM | $-142.11MM | $-322.93MM |
| Capital expenditure | $0.13MM | $0.14MM | $0.66MM |
| Investing Cash Flow | $-587.77MM | $-205.34MM | $-174.31MM |
| Financing Cash Flow | $86.51MM | $381.23MM | $617.53MM |
| Earnings Per Share** | $-0.99 | $-0.31 | $-1.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.